The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.

Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.

Claudin18.2 is out, but the US big pharma opts in to a new project.

The company sticks with EZH2, despite others adding EZH1 inhibition.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.